Plain-English translation of NCT07616427 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a personalized treatment approach for a specific type of early breast cancer using combined with hormone therapy and HER2-targeted drugs. The doctors will check how well your tumor responds after an initial period of treatment. If your cancer responds well, you'll continue the same medications; if not, they'll switch you to chemotherapy before surgery.
Doctors want to find ways to treat this type of breast cancer effectively without giving all patients chemotherapy upfront, since chemotherapy can have serious side effects. This medication is designed to work alongside existing hormone and HER2 therapies to spare some patients from unnecessary chemotherapy while still getting excellent results.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication along with hormone therapy and HER2-targeting drugs before surgery. After an initial treatment period, doctors will scan your tumor to see how well it's responding. Depending on your response, you'll either continue the same treatment or switch to chemotherapy combined with HER2 drugs. After surgery, your doctors will decide on additional treatment based on how your cancer responded. You'll have regular clinic visits, blood tests, and imaging scans throughout the study.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China